Novartis to report Cosentyx data at AAD 2015

Novartis has announced that it will be presenting new clinical data on its human monoclonal antibody therapy Cosentyx at the annual meeting of the American Academy of Dermatology (AAD).

The company will be highlighting 25 posters from the Novartis Dermatology portfolio during the congress in San Francisco from March 20th to 24th, including a total of 18 Cosentyx abstracts.

New data from the head-to-head CLEAR study will include results that demonstrate Cosentyx is superior to an established alternative in clearing skin among patients with moderate-to-severe plaque psoriasis.

Additionally, new long-term results from the phase III programme monitoring the drug's performance for up to two years will be highlighted for the first time at the congress.

Vasant Narasimhan, global head of development at Novartis Pharmaceuticals, said: "Our commitment is to keep demonstrating more evidence on the ability of Cosentyx to clear psoriasis skin, to inform physicians and give hope to people living with this lifelong disease who need treatments that provide long-term relief."

The drug has been approved as a plaque psoriasis therapy in the EU, US, Switzerland, Chile, Australia and Canada, while it has an additional indication as an active psoriatic arthritis therapy in Japan.